Autologous Transplantation of BM-ECs With Platelet-Rich Plasma Extract for the Treatment of Critical Limb Ischemia
Primary Purpose
Leg Ulcer, Diabetic Foot, Gangrene
Status
Unknown status
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
BM-ECs and PRPE
BM-ECs
Sponsored by
About this trial
This is an interventional treatment trial for Leg Ulcer
Eligibility Criteria
Inclusion Criteria:
Limb ischemia patients(e.g. arteriosclerosis obliterans,diabetic critical limb ischemia, thromboangitis obliterans)
- 18 Years to 80 Years (Adult, Senior);
- Have ability to understand and comply with the study requirements, and provide the written informed consent prior to any procedures ;
Patient meets at least one of the following diagnostic criteria for the index limb:
- ABI<0.7mmHg
- TcpO2 <40 mm Hg
- Or, nonhealing ulcer due to local arterial compromise with no opportunity for revascularization;
- Have no improvement after conservative treatment and are not suitable for surgical bypass surgery because no outflow tract of diseased vessel can be found by imaging;
- Despite having good outflow artery, but the elderly and frail patients can also not tolerate revascularization or interventional surgery;
- Unlikelihood of major amputation of the leg during the next 12 months;
- Expected life span more than 2 years.
Exclusion Criteria:
- Pregnant or lactating;
- Diabetics with poorly controlled blood glucose levels (defined as HbA1c>7% and/or proliferative retinopathy);
- Patients with decompensated cardiac, renal or liver disease;
- Patients with confirmed malignant tumor;
- Subjects are with serious heart, liver, kidney and lung failure or under poor general condition that are inability to undergo bone marrow harvesting and transplantation;
- Known or suspected disease of the immune system or osteomyelitis;
- Inability to sign informed consent form and to comply with the schedule of the study;
- There has reason to suspect that the patient is forced to join the study;
- Any other condition, in the opinion of the investigator, would render the patient unsuitable for the study.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
BM-ECs and PRPE
BM-ECs
Arm Description
Multipoint of intramuscular injections into ischemic limbs.Injections composed of bone marrow derived endothelial cells (BM-ECs) and platelet-rich plasma extract (PRPE).
Intramuscular injection of bone marrow derived endothelial cells only.
Outcomes
Primary Outcome Measures
Survival without major amputation
Secondary Outcome Measures
Perfusion rate in treated tissue by measure of ankle-brachial index (ABI)
Perfusion rate in treated tissue by transcutaneous PO2 (TcPO2)
Perfusion rate in treated tissue by digital subtraction angiography (DSA)
wound size
wound stage
Pain intensity
Pain intensity using Visual Analogue Scale
Thermography
Full Information
NCT ID
NCT02993809
First Posted
November 23, 2016
Last Updated
December 13, 2016
Sponsor
South China Research Center for Stem Cell and Regenerative Medicine
1. Study Identification
Unique Protocol Identification Number
NCT02993809
Brief Title
Autologous Transplantation of BM-ECs With Platelet-Rich Plasma Extract for the Treatment of Critical Limb Ischemia
Study Type
Interventional
2. Study Status
Record Verification Date
September 2016
Overall Recruitment Status
Unknown status
Study Start Date
March 2018 (undefined)
Primary Completion Date
December 2019 (Anticipated)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
South China Research Center for Stem Cell and Regenerative Medicine
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The intent of this clinical study is to evaluate the safety of the injection composed of autologous bone marrow derived endothelial cells (BM-ECs) and platelet-rich plasma extract (PRPE) for the treatment of critical limb ischemia.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Leg Ulcer, Diabetic Foot, Gangrene, Peripheral Vascular Disease, Ischemia
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
40 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
BM-ECs and PRPE
Arm Type
Experimental
Arm Description
Multipoint of intramuscular injections into ischemic limbs.Injections composed of bone marrow derived endothelial cells (BM-ECs) and platelet-rich plasma extract (PRPE).
Arm Title
BM-ECs
Arm Type
Active Comparator
Arm Description
Intramuscular injection of bone marrow derived endothelial cells only.
Intervention Type
Biological
Intervention Name(s)
BM-ECs and PRPE
Intervention Type
Biological
Intervention Name(s)
BM-ECs
Primary Outcome Measure Information:
Title
Survival without major amputation
Time Frame
6 months after implantation
Secondary Outcome Measure Information:
Title
Perfusion rate in treated tissue by measure of ankle-brachial index (ABI)
Time Frame
Within 6 months after implantation
Title
Perfusion rate in treated tissue by transcutaneous PO2 (TcPO2)
Time Frame
Within 6 months after implantation
Title
Perfusion rate in treated tissue by digital subtraction angiography (DSA)
Time Frame
Within 6 months after implantation
Title
wound size
Time Frame
Within 6 months after implantation
Title
wound stage
Time Frame
Within 6 months after implantation
Title
Pain intensity
Description
Pain intensity using Visual Analogue Scale
Time Frame
Within 6 months after implantation
Title
Thermography
Time Frame
Within 6 months after implantation
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Limb ischemia patients(e.g. arteriosclerosis obliterans,diabetic critical limb ischemia, thromboangitis obliterans)
18 Years to 80 Years (Adult, Senior);
Have ability to understand and comply with the study requirements, and provide the written informed consent prior to any procedures ;
Patient meets at least one of the following diagnostic criteria for the index limb:
ABI<0.7mmHg
TcpO2 <40 mm Hg
Or, nonhealing ulcer due to local arterial compromise with no opportunity for revascularization;
Have no improvement after conservative treatment and are not suitable for surgical bypass surgery because no outflow tract of diseased vessel can be found by imaging;
Despite having good outflow artery, but the elderly and frail patients can also not tolerate revascularization or interventional surgery;
Unlikelihood of major amputation of the leg during the next 12 months;
Expected life span more than 2 years.
Exclusion Criteria:
Pregnant or lactating;
Diabetics with poorly controlled blood glucose levels (defined as HbA1c>7% and/or proliferative retinopathy);
Patients with decompensated cardiac, renal or liver disease;
Patients with confirmed malignant tumor;
Subjects are with serious heart, liver, kidney and lung failure or under poor general condition that are inability to undergo bone marrow harvesting and transplantation;
Known or suspected disease of the immune system or osteomyelitis;
Inability to sign informed consent form and to comply with the schedule of the study;
There has reason to suspect that the patient is forced to join the study;
Any other condition, in the opinion of the investigator, would render the patient unsuitable for the study.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Xuetao Pei, M.D., Ph.D
Phone
8610-68164807
Email
AMMS0906@163.com
First Name & Middle Initial & Last Name or Official Title & Degree
Fang Fang, Ph.D
Phone
8620-89199011
Email
fangfang@scrm.org.cn
12. IPD Sharing Statement
Plan to Share IPD
Yes
Learn more about this trial
Autologous Transplantation of BM-ECs With Platelet-Rich Plasma Extract for the Treatment of Critical Limb Ischemia
We'll reach out to this number within 24 hrs